Marinomed Biotech AG
Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution
Marinomed Biotech AG
Wien, 24.9.2024
Overview ☐ Notification made after deadline Caution: In case of violations of major holdings notification rules, please pay attention to Section 137 BörseG 2018 (Suspension of voting rights)
1. Issuer: Marinomed Biotech AG 2. Reason for the notification: Event changing the breakdown of voting rights 3. Person subject to notification obligation 4. Name of shareholder(s): 5. Date on which the threshold was crossed or reached: 18.9.2024
6. Total positions
Details 7. Notified details of the resulting situation:
8. Information in relation to the person subject to the notification obligation: ☒ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. ☐ Full chain of controlled undertakings through which the voting rights and/or the financial/other instruments are effectively held starting with the ultimate controlling natural person or legal entity:
9. In case of proxy voting Date of general meeting: – Voting rights after general meeting: – is equivalent to – voting rights. 10. Sonstige Kommentare: Per 18. September 2024 erfolgte eine 10%ige Kapitalerhöhung des Grundkapitals der Marinomed AG (ATMARINOMED6). Die Österreichische Beamtenversicherung, Versicherungsverein auf Gegenseitigkeit, hat an dieser Kapitalerhöhung nicht teilgenommen und hält unverändert 62.916 Aktien der Gesellschaft. Ihr Anteil an der Marinomed AG reduzierte sich dadurch von 4,08% auf 3,71%.
Wien am 24.9.2024
26.09.2024 CET/CEST |
Language: | English |
Company: | Marinomed Biotech AG |
Hovengasse 25 | |
2100 Korneuburg | |
Austria | |
Internet: | www.marinomed.com |
End of News | EQS News Service |